[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"imaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:imaging":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,82,106,127,165,199,221,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":4,"leadSponsor":43,"locationsCount":46},"100061867","mri-study-of-musculoskeletal-function-100061867",false,"NCT00051857","MRI Study of Musculoskeletal Function","Virtual Function Anatomy (VFA)","* INCLUSION CRITERIA:\n\nAffected Participants:\n\n* Must be between the ages of 5-95 years.\n* Minors \\\u003C 18 years of age, they must be capable of providing assent (verbal or written) with parental or legal guardian permissions obtained.\n* Adults 18 \\>= years of age, they must be able to provide informed consent.\n* Have the presence of a bone, muscle, soft tissue, connective tissue injury, impairment or related muscular skeletal system pathology.\n* Ability to have an MRI Scan.\n\nHealthy Volunteer Participants\n\n* Must be between the ages of 5-95 years.\n* Minors \\\u003C 18 years of age, they must be capable of providing assent (verbal or written) with parental or legal guardian permissions obtained.\n* Adults 18 \\>= years of age, they must be able to provide informed consent.\n* Ability to have an MRI Scan.\n\nEXCLUSION CRITERIA:\n\nAffected Participants:\n\n-For the MR imaging portion of this study, all participants must complete the NIH Diagnostic Radiology screening questionnaire. If any potential contraindication is found, either the volunteer s doctor (with knowledge of the potential contraindication) or the radiology department at the NIH will be contacted to determine if the potential contraindication would exclude them from the specific MR scans being proposed.\n\nHealthy Volunteer Participants\n\n* Any relevant medical problems\n* Clinical signs of an impairment in the joint\u002Flimb being studied.\n* Any serious injury to the joint\u002Flimb being studied, previous surgery on the joint\u002Flimb being studied or extreme pain at the joint\u002Flimb being studied.\n* Neurologic Pathology affecting the muscular skeletal system\n* For the MR imaging portion of this study, all participants must complete the NIH Diagnostic Radiology screening questionnaire. If any potential contraindication is found, either the volunteer s doctor (with knowledge of the potential contraindication) or the radiology department at the NIH will be contacted to determine if the potential contraindication would exclude them from the specific MR scans being proposed.",true,"ALL","5 Years","95 Years",{"count":21,"type":22},750,"ESTIMATED","OBSERVATIONAL","This study will use magnetic resonance imaging (MRI) and ultrasound images to study how muscles, tendons, and bones work together to cause motion. The procedure is one of several tools being developed to characterize normal and impaired musculoskeletal function, with the goal of developing improved methods of diagnosis and treatment of movement disorders.\n\nHealthy normal volunteers must be age 5 to unlimited, with or without joint impairment, may be eligible for this study. Volunteers with joint impairment may not have serious injury to the joint being studied, previous surgery on the joint being studied, or extreme pain at the joint being studied.\n\nMRI uses a strong magnet and radio waves to create images of the inside of the body. The subject lies on a long narrow couch inside a metal cylinder (the scanner) for up to 3 hours while the scanner gathers data. Earplugs are worn to muffle loud noises caused by electrical switching of radiofrequency circuits used in the scanning process. A special pad or tube may be placed over or around the region being scanned to improve the quality of the data. The subject will be asked to repeatedly move a specific joint, such as the knee, for brief periods, usually less than 5 minutes. The subject can communicate via intercom with the person performing the study at all times during the procedure, and may request to stop the study at any time.\n\n...",[26,27,28],"Abnormalities","Imaging","Patellofemoral Pain Syndrome",[30,31,32,33,34,35],"Patello-Femoral","Knee","Motion","MRI","Kinematics","Natural History","RECRUITING","2026-06-27",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2003-03-05",{"name":44,"class":45},"National Institutes of Health Clinical Center (CC)","NIH",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100504659","mechanisms-of-disease-progression-in-aortic-stenosis---the-modas-study-100504659","NCT05851209","Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study","Evaluation of Immunologic and Image Morphologic Parameters to Predict Disease Progression in Patients With Moderate Aortic Valve Stenosis","Inclusion Criteria:\n\n* The patient has an acquired (tricuspid) moderate aortic valve stenosis, which is the reason for regular outpatient cardiological care.\n* The subject has been informed verbally and in writing about the study and has given written consent to participate in this study.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* The subject has contraindications for the performance of a magnetic resonance imaging or computed tomography (e.g., severe arrhythmias , contrast agent intolerance, a pacemaker, or severe renal insufficiency or severe renal insufficiency or claustrophobia).\n* Presence of only mild or already high-grade acquired tricuspid Aortic valve stenosis\n* Patient with bicuspid aortic valve\n* Inability to follow the instructions of study personnel\n* Lack of written informed consent","18 Years",{"count":56,"type":22},938,"Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the development of hemodynamically relevant aortic valve stenosis in order to identify high-risk patients and to develop further therapeutic options.",[59,27,60,61,62,63],"Aortic Stenosis","Pathogenesis","Disease Progression","Aortic Valve Calcification","Genetics",[65,66,67,68,69,70,71],"severe aortic stenosis","disease progression","pathogenesis of degenerative aortic stenosis","early detection","Cardiovascular magnet resonance","Transthoracal echocardiography","computertomography","2026-06-26",{"date":39,"type":40},{"date":75,"type":40},"2023-07-01",{"date":77,"type":22},"2031-07",{"name":79,"class":80},"Heinrich-Heine University, Duesseldorf","OTHER",3,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":90,"conditions":91,"keywords":95,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":46},"100599663","ai-driven-multimodal-imaging-integration-for-diagnosis-and-prognostication-of-digestive-system-diseases-100599663","NCT07087418","AI-Driven Multimodal Imaging Integration for Diagnosis and Prognostication of Digestive System Diseases","Inclusion Criteria:\n\n* Patients with multimodal-confirmed diagnoses (clinical, imaging, endoscopic, and pathological) of:\n\n  * Inflammatory bowel disease (IBD; Crohn's disease or ulcerative colitis)\n  * Intestinal tuberculosis\n  * Behçet's disease\n* Availability of ≥1 technically adequate CT or MR scan with high-quality colonoscopy performed within ±1 month of imaging.\n\nExclusion Criteria:\n\n* ・Suboptimal imaging quality (e.g., low-dose artifacts, metal artifacts)\n\n  * Inadequate bowel preparation for endoscopy\n  * Incomplete examinations due to poor tolerance",{"count":89,"type":22},5000,"The goal of this observational, retrospective and prospective study is to develop a noninvasive disease assessment system by leveraging artificial intelligence (AI) to comprehensively analyze multi-modal imaging features, including magnetic resonance enterography (MRE) and computed tomography enterography (CTE), for the diagnosis and prognostication of digestive diseases. To this end, the investigators retrospectively enrolled imaging, endoscopic, and clinical data from 21 centers across China to construct and iteratively optimize the AI model. The model's performance will be prospectively validated in two centers, and its accuracy in lesion localization will be verified through real-world deployment in endoscopy suites.",[92,93,94,27],"Digestive Diseases","Radiology","AI (Artificial Intelligence)",[93,27,92,96],"Artificial Intelligence","2026-04-08",{"date":99,"type":40},"2026-04-13",{"date":101,"type":40},"2025-07-01",{"date":103,"type":22},"2026-08-01",{"name":105,"class":80},"First Affiliated Hospital, Sun Yat-Sen University",{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":46},"100557905","can-imaging-be-an-alternative-to-exercise-testing-as-a-predictor-of-surgical-fitness-100557905","NCT06544187","Can Imaging be an Alternative to Exercise Testing as a Predictor of Surgical Fitness?","RESPIRE","Inclusion Criteria:\n\nInclusion criteria for patients (cohort 1)\n\n* Patients diagnosed oesophageal\u002Fgastric or pancreatic cancer.\n* Patients who have or a under consideration for a CPET investigation.\n* Aged ≥ 18.\n* Existing UHNM Patient.\n* Willing and able to give fully informed consent.\n* Willing and able to comply with the study procedures.\n\nInclusion criteria for staff volunteers (cohort 2)\n\n* Aged ≥ 18 years.\n* Willing and able to give fully informed consent.\n* Willing and able to comply with the study procedures.\n* UHNM member of staff.\n\nExclusion Criteria:\n\nExclusion criteria for patients (cohort 1)\n\n* Patients with contraindications to MRI due to safety at 3T.\n* Patients with metalwork within the imaging field of view (e.g., knee replacement).\n* Claustrophobic patients.\n* Patients outside of stated age range to ensure informed consent.\n* Patients not referred for CPET investigations.\n* Patients that are pregnant.\n* Patients that are unable to communicate in English.\n* Patients lacking the capacity and capability to give fully informed consent.\n* Patients participating in any other interventional studies with a contraindication to their participation.\n* Patients for whom the addition of an MRS scan would delay any part of their standard treatment pathway.\n* History of diabetes.\n\nExclusion criteria for staff volunteers (cohort 2)\n\n* Volunteers with contraindications to MRI due to safety at 3T.\n* Volunteers with metalwork within the imaging field of view (e.g., knee replacement).\n* Claustrophobic volunteers.\n* Volunteers outside of stated age range to ensure informed consent.\n* Volunteers that are pregnant.\n* Volunteers that are unable to communicate in English.\n* Volunteers lacking the capacity and capability to give fully informed consent.\n* Volunteers participating in any other interventional studies with a contraindication to their participation.\n* Known or suspected medical conditions pertinent to the area being scanned.\n* History of diabetes.",{"count":114,"type":22},56,"This study aims to explore an alternative method for assessing a participant's readiness for surgery, specifically for those undergoing surgery for gastric, oesophageal, or pancreatic cancer. Surgery for these diseases is extremely demanding on the body and surgeons need to be confident that a patient can tolerate the procedure.\n\nTraditionally, participants undergo Cardiopulmonary Exercise Tests (CPET) to determine their fitness for surgery. This involves cycling on an exercise bike with increasing resistance until the resistance is too great to continue cycling at a constant rate. An individual's maximum rate of oxygen consumption (VO2max) and the anaerobic threshold (AT) are calculated during CPET and used by surgeons as a predictor for surgical fitness. CPET tests can be physically demanding for participants and are very resource intensive. Furthermore, some patients may not be able to tolerate exercise tests due to physical constraints.\n\nAn alternative method, Magnetic Resonance Spectroscopy (MRS), could be used to measure an individual's fitness prior to surgery. Within this study, MRS will be used to determine the levels of fat within the thigh muscle, which in turn may be able to be used to predict fitness for surgery.\n\nThe first phase includes recruiting participants on the surgical pathway. MRS will be performed as an additional examination, typically on the same day as the CPET. Fat levels determined from MRS will be compared with conventional CPET outcomes (VO2max and AT). This analysis aims to determine if MRS derived fat levels correlates with VO2max and AT and, if correlation is high, potentially providing an alternative to CPET for patients who cannot tolerate exercise tests.\n\nThe second phase involves recruiting volunteers who will undergo repeated MRS scans to assess the reliability of MRS methods. This process allows us to understand the consistency of MRS derived fat levels over both short and long-term intervals.\n\nThe potential benefits of this project include an additional pathway for assessing fitness for surgery or enhancing the presurgical pathway for patients by providing an alternative method for fitness assessment. This study aims to provide evidence that could present an alternative method of assessing a patient's fitness for surgery. The goal is to explore an alternative that may complement or refine current practices in preoperative assessments.",[117,27],"Surgical Fitness","2026-03-25",{"date":120,"type":40},"2026-03-27",{"date":122,"type":40},"2025-01-06",{"date":124,"type":22},"2026-12",{"name":126,"class":80},"University Hospitals of North Midlands NHS Trust",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":138,"phases":139,"briefSummary":141,"conditions":142,"keywords":151,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":46},"100564857","early-phase-1-imagemhtt-009--fih-evaluation-of-novel-mutant-huntingtin-pet-radioligand-11cchdi-00491009-100564857","NCT06634628","iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009","First in Human Adaptive Study to Investigate the Kinetic Properties of the Novel PET Radioligand [11C]CHDI-00491009 and Its Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of People With Huntington's Disease","iMagemHTT-009","Inclusion Criteria:\n\nPwHD HD-ISS Stages 2 and 3 and HC participants who:\n\n1. Are female or male adults, age 18-64 years old, inclusive.\n2. Have body mass index (BMI) between 19 and 35, inclusive.\n3. Have capacity to give full informed consent in writing and have read and signed the informed consent form (ICF).\n4. Are able to comply with study procedures, including fasting and blood sampling.\n5. Are able and willing to travel to the imaging center in Leuven, Belgium.\n6. Are willing to comply with the use of adequate contraceptive measures.\n\n   HD-ISS Stage 2 participants who:\n7. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and\n8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.\n9. Have a PIN score of 0.47 to 1.84 \\[prognostic index normed for HD (PIN) where PIN = (PIHD - 883)\u002F1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)\\].\n\nHD-ISS Stage 2 participants who:\n\n7\\. Have a huntingtin gene CAG expansion between 40 and 50, inclusive; and 8. Are classified within HD-ISS Stage 2 per the HD-ISS criteria using HD-ISS Modified Stage calculator.\n\n9\\. Have a PIN score of 0.47 to 1.84 \\[prognostic index normed for HD (PIN) where PIN = (PIHD - 883)\u002F1044 where PIHD = 51 x TMS + (-34) x SDMT + 7 x Age x (CAG - 34) (TMS is the UHDRS Total Motor Score, and SDMT is the UHDRS Symbol Digit Modalities Test)\\].\n\nHC participants who:\n\n13\\. Have no known family history of HD; or 14. Have a known family history of HD and have been tested for the huntingtin gene CAG expansion and are not at genetic risk for HD (CAG \\\u003C 36).\n\n15\\. Age match (+\u002F- 5 years) and biological sex match to each HD participant in Cohort 2 and Cohort 3 (except for Cohort 1, no matching).\n\nExclusion Criteria:\n\nPwHD HD-ISS Stages 2 and 3 and HC participants who:\n\n1. Are currently participating in, or are less than 30 days after completing participation in, other therapeutic or imaging studies.\n2. Have previously participated in a PET imaging study in the past 12 months that, cumulatively with the current study, will exceed annual regulatory limits for radiation exposure.\n3. Have any disease, condition, or concomitant medication that significantly compromises the function of the body systems and that, in the opinion of the Investigator, might interfere with the conduct of the study or its interpretation.\n4. Are pregnant and breastfeeding females.\n5. Have concomitant use of antiplatelet or anticoagulant therapy (inclusive of acetylsalicylic acid).\n6. Have a bleeding disorder.\n7. Have a needle phobia.\n8. Have any metal objects present in the body that are incompatible with MRI.\n9. Have metal objects present in the body that are compatible with MRI and are located in the head or neck.\n10. Have any clinically significant results on safety laboratory tests that, in the opinion of the Investigator, would either put the participant at risk or interfere with the conduct of the study or interpretation of data. These tests include, but are not limited to:\n\n    * a. positive results for HBsAg, HepC, HIV-1 or HIV-2 (will also be reported as required by local\u002Fnational regulations),\n    * b. clinically significant, abnormal results for safety laboratory tests.\n\n    PwHD participants who:\n11. If they are using any antidepressant, psychoactive, psychotropic or other medications or nutraceuticals used to treat HD, the use of inappropriate (e.g., non-therapeutically high) or unstable dose within 30 days prior to participation.\n\n    HC participants who:\n12. Have a family history of HD and have not been tested for the huntingtin gene (CAG) expansion.","64 Years",{"count":137,"type":22},27,"INTERVENTIONAL",[140],"EARLY_PHASE1","This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand \\[11C\\]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD).\n\nThe study is divided into three cohorts defined by the Huntington's Disease Integrated Staging System (HD-ISS): Cohort 1 - initial tracer validation (3 healthy controls (HCs)); Cohort 2 - target validation and test-retest variability (6 HD-ISS Stage 3 participants and 6 age and biological sex-matched HCs); Cohort 3 - target sensitivity (6 HD-ISS Stage 2 participants and 6 age and biological sex-matched HCs). An interim analysis (IA) will be conducted after the completion of each cohort, followed by a final analysis for the study.\n\nIn addition to imaging, exploratory biomarkers, including somatic instability index, soluble mHTT and total huntingtin (HTT), will be assessed. All participants with HD (PwHD) will have an additional blood sample drawn at the screening visit to assess the somatic instability index and will also be invited to provide an optional cerebrospinal fluid (CSF) sample for measurement of soluble mHTT and total HTT.",[143,144,145,146,147,27,148,149,150],"Huntington Disease","HD","PET Tracer","Positron Emission Tomography","Radioligand","mHTT","Huntington's","Huntington's Disease",[152,143,144,145,146,153,154,148,155,150],"iMagemHTT","radioligand","imaging","huntingtin","2026-03-12",{"date":158,"type":40},"2026-03-13",{"date":160,"type":40},"2026-02-24",{"date":162,"type":22},"2028-03",{"name":164,"class":80},"CHDI Foundation, Inc.",{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":138,"phases":175,"briefSummary":177,"conditions":178,"keywords":183,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":46},"100613903","phase-1-a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors-100613903","NCT07272642","A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.","A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Monoclonal Antibody Targeting the LRRC15 Epitope, in Participants With Locally Advanced or Metastatic Solid Tumors","DUNP19","Inclusion Criteria:\n\n1. Participant is willing and able to give written informed consent prior to start of any study procedures and assessments and must be willing to comply with all study procedures.\n2. Participant is ≥ 18 years of age at the time of signing the informed consent.\n3. Participant has a documented history of incurable, histopathologically confirmed CRC, HNSCC,NSCLC (squamous or non-squamous histology) or TNBC with either locally advanced disease which has progressed despite (or is ineligible for) available radical standard of care treatments and has subsequently exhausted available standard of care palliative intent systemic therapies or established metastatic disease where available standard of care systemic therapies have been exhausted.\n4. Has had a SOC CT or MRI scan within 8 weeks prior to signing informed consent that indicates the presence of at least 1 site of new or residual disease. SOC baseline images must be available for submission to the centralized imaging reader as reference\n5. Participant must provide an archived tumor tissue sample.\n6. Participant has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1.\n7. Participant has at least 1 visceral lesion that has not been treated with external beam radiation therapy (EBRT).\n8. Participants of childbearing potential (CBP) must have a negative beta-human chorionic gonadotropin (β-hCG) test and must not be breastfeeding. Participants of CBP are defined as those who are not surgically sterile or post-menopausal. Participants will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. Participants \\\u003C 50 years of age who meet the criteria for postmenopausal status without previous surgical sterilization should be considered for further investigation with luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels to confirm serological post-menopausal status.\n9. Participants of CBP must agree to use a highly effective method of contraception during the study and for 3 months after the injection of LNTH-2403.\n10. Male participants who are able to father a child must agree to avoid impregnating a partner and to adhere to a highly effective method of contraception during the study and for 3 months after the injection of LNTH-2403. All male participants must agree to not donate sperm during the study and for 3 months after the injection of LNTH-2403.\n\nExclusion Criteria:\n\n1. Has any medical condition that would, in the Investigator's judgment, prevent the participant's full participation in the clinical study due to safety concerns or compliance with clinical study procedures.\n2. Has a history of uncontrolled allergic reactions and\u002For known or expected hypersensitivity to protein therapeutics, LNTH-2403, or any of its excipients.\n3. Has inadequate organ functions as reflected in laboratory parameters:\n\n   1. Estimated glomerular filtration rate (eGFR) (calculated using the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] equation) ≤ 50 mL\u002Fmin\u002F1.73m2\n   2. Platelet count \\\u003C100 x 10\\^9 \u002FL\n   3. Hemoglobin \\\u003C 9 g\u002FdL\n   4. Absolute neutrophil count \\\u003C 1.0 × 109\u002FL\n   5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 x upper limit of normal (ULN), or ≥ 5 x ULN for participants with known liver metastases\n   6. Total bilirubin ≥ 1.5 x ULN, except for participants with documented Gilbert's syndrome who are eligible if total bilirubin is ≤ 3 x ULN\n   7. For participants not taking warfarin or other anticoagulants: international normalized ratio (INR) ≤ 1.5 or prothrombin time (PT) ≤ 1.5 × ULN; and either partial thromboplastin time or activated partial thromboplastin time (PTT or aPTT) ≤ 1.5 × ULN. Participants taking warfarin must be on a stable dose that results in a stable INR \\\u003C 3.5. Among participants receiving other anticoagulant therapy, PT or aPTT must be within the intended therapeutic range of the anticoagulant.\n4. Has clinically significant cardiovascular\u002F cerebrovascular disease defined as cerebral vascular accident, stroke, carotid artery disease transient ischemic attack (\\\u003C 6 months prior to enrollment), myocardial infarction (\\\u003C 6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class \\>II) or serious cardiac arrhythmia.\n5. Has a marked baseline prolongation of QT\u002FQTc interval (repeated demonstration of a QTc interval calculated with Fredericia's correction (QTcF) \\> 470 msec for females and QTcF \\> 450 msec for males);\n6. Has a history of or has additional risk factors for torsade's de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n7. Is participating in an interventional trial or has received an investigational anticancer agent within 5 half-lives of the time of informed consent signature or is expected to enroll in an interventional trial on or before the imaging timepoint during Days 3-5.\n8. Has been treated with an LRRC15-targeted investigational product.\n9. Has had a PET scan done within 10 physical half-lives of the PET imaging agent prior to receiving study intervention.\n10. Is pregnant or breastfeeding.\n11. Had or is scheduled to have major surgery within 4 weeks of Day 1 (not including diagnostic laparoscopy).\n12. Has a medical history, physical examination, or clinical laboratory test suggestive of a condition, disorder, or disease that could adversely affect drug absorption, distribution, metabolism, or elimination of LNTH-2403, including chronic liver or renal failure.",{"count":174,"type":22},16,[176],"PHASE1","LNTH-2403 (177Lu-DOTA-DUNP19) is a lutetium-177 radiolabeled, fully humanized monoclonal antibody (mAb) that binds with high specificity and affinity to leucine-rich repeat containing 15 (LRRC15), a transforming growth factor (TGF) - β-driven biomarker expressed on the cell membrane of cancer cells and\u002For cancer-associated fibroblasts 9CAFs) in select tumor types. Upon binding, LNTH-2403 is rapidly internalized, such that it can serve as a dual-purpose agent for both non-invasive imaging and radiotheranostic treatment of LRRC15- positive tumors. This first-in-human (FIH) imaging study will evaluate the safety and imaging of LNTH-2403 in participants with locally advanced or metastatic solid tumors.",[27,179,180,181,182],"Colorectal Cancer","Head and Neck Squamous Cell Carcinoma","Non-Small Cell Lung Cancer","Triple Negative Breast Cancer (TNBC)",[154,184,185,186,187],"colorectal cancer","Head and Neck squamous cell carcinoma,","non-small cell lung cancer,","triple negative breast cancer","NOT_YET_RECRUITING","2026-02-23",{"date":191,"type":40},"2026-02-25",{"date":193,"type":22},"2026-01-30",{"date":195,"type":22},"2027-10-31",{"name":197,"class":198},"Radiopharm Theranostics, Ltd","INDUSTRY",{"id":200,"slug":201,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":4,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":208,"conditions":209,"keywords":210,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":46},"100600058","evaluation-of-c-arm-pcd-cbct-for-image-guided-interventions-100600058","NCT07092553","Evaluation of C-arm PCD-CBCT for Image-Guided Interventions","Evaluation of C-arm Photon Counting Detector Cone Beam CT (PCD-CBCT) for Image-Guided Interventions","Inclusion Criteria:\n\n* Not pregnant or breastfeeding\n* Scheduled to receive image-guided intervention (IGI) of the head or the body\n* Pre-treatment multidetector computed tomography (MDCT) images available\n\nExclusion Criteria:\n\n* Unable to provide informed consent on their own behalf due to cognitive impairment\n* Pregnant or breastfeeding",{"count":207,"type":22},20,"The overarching objective of the project is to develop a new C-arm interventional x-ray imaging platform that integrates both a photon counting detector and a flat panel detector to provide high image quality and quantitative spectral computed tomography (CT) image guidance will be developed to enable more accurate and safe interventional procedures for patients.",[27],[211],"image-guided intervention","2026-02-12",{"date":214,"type":40},"2026-02-17",{"date":216,"type":22},"2026-06",{"date":218,"type":22},"2028-06",{"name":220,"class":80},"University of Wisconsin, Madison",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":188,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":242,"locationsCount":4},"100621803","assessment-of-a-3d-printed-extraoral-camera-assembly-for-standardized-dental-photography-100621803","NCT07375368","Assessment of a 3D-Printed Extraoral Camera Assembly for Standardized Dental Photography","Evaluation of a 3D-Printed Extraoral Camera Assembly for Standardization of Dental Photography:A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Adult volunteers aged 18-40 years.\n* Intact anterior dentition and healthy periodontal tissues.\n* Cooperative and able to maintain a standardized head position. Only intraoral photographs will be taken\n\nExclusion Criteria:\n\n* Facial deformities or scars affecting the image region.\n* Previous orthognathic or periodontal plastic surgery altering soft-tissue contour.\n* Active dermatologic lesions or tattoos in the perioral area.","40 Years",{"count":207,"type":22},"This study investigates whether a 3D-printed extraoral camera assembly improves the reproducibility and dimensional standardization of dental photographs compared with conventional DSLR photography using standardized settings. The assembly, serving as the index test, standardizes camera position, distance, and angle during image capture, allowing performance comparison with traditional DSLR methods under identical exposure and lighting conditions. By enhancing photographic consistency, the assembly aims to improve longitudinal periodontal records, esthetic documentation, and digital analyses, providing a non-contact, operator-independent tool for reliable visual comparisons across clinical sessions.",[27],[233,234,235],"3D-printed extraoral camera","standardization","extraoral camera","2026-01-24",{"date":238,"type":40},"2026-01-29",{"date":240,"type":22},"2026-01-20",{"date":193,"type":22},{"name":243,"class":80},"Cairo University",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":251,"targetDuration":4,"studyType":138,"phases":253,"briefSummary":255,"conditions":256,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":46},"100566970","phase-2-a-study-of-bevonescein-in-patients-undergoing-abdominopelvic-surgery-100566970","NCT06662097","A Study of Bevonescein in Patients Undergoing Abdominopelvic Surgery","Multicenter Open-Label Feasibility Study of Intraoperative Nerve and Ureter Visualization With Bevonescein in Patients Undergoing Minimally Invasive Abdominopelvic Surgery","Inclusion Criteria:\n\n* Must be a minimum of 18 years of age\n* Study participant is planning to proceed with surgery\n* Willing to provide informed consent\n* Sexually active patients must be willing to use an acceptable form of contraceptive while participating and 30 days after.\n* Females of childbearing potential must have a negative pregnancy test at screening and during the study.\n\nExclusion Criteria:\n\n* Patient has had prior surgery at the intended surgical site.\n* Patient has abnormal cardiac rhythm not controlled by medication.\n* Patient has moderate to severe renal impairment.\n* Patient has a history of fluorescein allergy.\n* Patient has a history of drug-related anaphylactic.\n* Presence of a concurrent disease or condition that may interfere with study participation.\n* Presence or history of any condition that, in the view of the investigator, places the patient at high risk of treatment compliance.\n* Use of any Investigational Product or investigational medial device within 30 days prior to screening.",{"count":252,"type":22},64,[254],"PHASE2","Feasibility study of Bevonescein to highlight Nerves and Ureter in patients undergoing Minimally Invasive Surgery",[257,258,27],"Surgery","Nerve Injury","2024-10-25",{"date":261,"type":40},"2024-10-28",{"date":263,"type":40},"2024-10-16",{"date":265,"type":22},"2025-09",{"name":267,"class":198},"Alume Biosciences, Inc."]